Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (161-170 of 264) with videos related to

Pageof 27
Sort By:
Blood|November 18, 2005
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistanceJoya Chandra, Jeannette Tracy, David Loegering, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 16, 2017
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive LeukemiasJorge E Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, et al.
Leukemia Research|April 29, 2019
Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]Aaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Blood|March 28, 2015
Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignanciesLuke F Peterson, Hanshi Sun, Yihong Liu, et al.
Blood|March 25, 2016
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Paul G Richardson, Todd M Zimmerman, Craig C Hofmeister, et al.
Cancer|August 28, 2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phaseSusan O'Brien, Francis Giles, Moshe Talpaz, et al.
Blood|January 10, 2012
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.
Cancer|February 6, 2003
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Pageof 27

Showing results (161-170 of 264) with videos related to

Sort By:
Pageof 27
Blood|November 18, 2005
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistanceJoya Chandra, Jeannette Tracy, David Loegering, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 16, 2017
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive LeukemiasJorge E Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, et al.
Leukemia Research|April 29, 2019
Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]Aaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Blood|March 28, 2015
Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignanciesLuke F Peterson, Hanshi Sun, Yihong Liu, et al.
Blood|March 25, 2016
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Paul G Richardson, Todd M Zimmerman, Craig C Hofmeister, et al.
Cancer|August 28, 2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phaseSusan O'Brien, Francis Giles, Moshe Talpaz, et al.
Blood|January 10, 2012
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.
Cancer|February 6, 2003
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Pageof 27